Study on UCART20x22 for Treating Relapsed or Hard-to-Treat B-Cell Non-Hodgkin Lymphoma

Inclusion Criteria

• Must have a performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have relapsed or refractory mature B-Cell Non-Hodgkin Lymphoma (B-NHL) that is positive for CD20 and/or CD22 markers.
• Eligible subtypes include:
  • For Dose-Finding Part: Relapsed or refractory mature B-NHL, excluding certain types like chronic lymphocytic leukemia and Burkitt's lymphoma.
  • For Dose-Expansion Part: Relapsed or refractory large B-cell lymphoma (LBCL), including specific subtypes like diffuse large B-cell lymphoma (DLBCL) and transformed follicular lymphoma.
• Must have tried at least two previous treatments, including specific drugs for different lymphoma types.
• Must have access to autologous stem cells if at high risk for blood-related side effects.

Exclusion Criteria

• Have used an investigational product recently, except for certain cell or gene therapies.
• Have had recent chemotherapy or targeted therapy for B-NHL.
• Have had monoclonal antibody therapy within 30 days.
• Have had recent cell or gene therapy targeting both CD20 and CD22.
• Have had a stem cell transplant recently.
• Have active graft versus host disease or need immunosuppressive treatment.
• Have had recent radiotherapy, except for specific cases.
• Have active or past central nervous system lymphoma.
• Have an active central nervous system disorder.
• Are taking more than 20 mg of prednisone daily.
• Have an active infection or history of certain infections.
• Have a history of allergy to alemtuzumab.
• Have uncontrolled heart disease.
• Have had major surgery recently.
• Have another uncontrolled cancer within the last two years.